Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Immunol. 2023 Mar 23;14:1174184. doi: 10.3389/fimmu.2023.1174184. eCollection 2023.
The corona virus disease 2019 (COVID-19) global pandemic has had an unprecedented and persistent impact on oncological practice, especially for patients with lung cancer, who are more vulnerable to the virus than the normal population. Indeed, the onset, progression, and prognosis of the two diseases may in some cases influence each other, and inflammation is an important link between them. The original chronic inflammatory environment of lung cancer patients may increase the risk of infection with COVID-19 and exacerbate secondary damage. Meanwhile, the acute inflammation caused by COVID-19 may induce tumour progression or cause immune activation. In this article, from the perspective of the immune microenvironment, the pathophysiological changes in the lungs and whole body of these special patients will be summarised and analysed to explore the possible immunological storm, immunosuppression, and immune escape phenomenon caused by chronic inflammation complicated by acute inflammation. The effects of COVID-19 on immune cells, inflammatory factors, chemokines, and related target proteins in the immune microenvironment of tumours are also discussed, as well as the potential role of the COVID-19 vaccine and immune checkpoint inhibitors in this setting. Finally, we provide recommendations for the treatment of lung cancer combined with COVID-19 in this special group.
2019 年冠状病 2019（COVID-19）全球大流行对肿瘤学实践产生了前所未有的持续影响，特别是对肺癌患者，他们比普通人群更容易感染病毒。事实上，这两种疾病的发病、进展和预后在某些情况下可能相互影响，而炎症是它们之间的重要环节。肺癌患者原有的慢性炎症环境可能会增加感染 COVID-19 的风险，并加重继发损伤。同时，COVID-19 引起的急性炎症可能会诱导肿瘤进展或引起免疫激活。在本文中，我们将从免疫微环境的角度，对这些特殊患者肺部和全身的病理生理变化进行总结和分析，探讨慢性炎症合并急性炎症可能引起的免疫风暴、免疫抑制和免疫逃逸现象。还讨论了 COVID-19 对肿瘤免疫微环境中的免疫细胞、炎症因子、趋化因子和相关靶蛋白的影响，以及 COVID-19 疫苗和免疫检查点抑制剂在这方面的潜在作用。最后，我们为这一特殊人群中 COVID-19 合并肺癌的治疗提供了建议。
